Maggiolo F, et al. - Researchers performed a prospective, open-label, multicentre, randomized trial in 36 European centers examining how switching from a regimen containing tenofovir disoproxil fumarate to one containing tenofovir alafenamide in virologically suppressed (HIV-1 RNA < 50 copies per mL) participants, aged 60 years and older, affects the bone mineral density of these patients. Between Dec 22, 2015, and March 21, 2018, 167 participants on a tenofovir disoproxil fumarate-containing regimen were randomly assigned (2:1) to open-label elvitegravir (150 mg), cobicistat (150 mg), emtricitabine (200 mg), and tenofovir alafenamide (10 mg) daily (n = 111 [66%]) or to continue therapy containing tenofovir disoproxil fumarate (300 mg) (n = 56 [34%]). Outcomes revealed achievement of significantly improved bone mineral density, overall safety, and efficacy in correlation to switching from a regimen containing tenofovir disoproxil fumarate to elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed people living with HIV aged 60 years or older. The data thereby support the feasibility of performing this switch.